image credit: Unsplash

Boehringer Ingelheim to boost antibody discovery with partner Twist

September 10, 2021


Boehringer Ingelheim will use the same concept in a new research collaboration with San Francisco-based Twist Bioscience, harnessing its antibody libraries to discover therapeutic antibodies that work against a range of BI targets.

Twist’s ability to manufacture DNA at scale has allowed it to construct proprietary antibody libraries precisely designed to match sequences that occur in the human body. This “library of libraries” and Twist’s expertise in the field “expedites antibody discovery by decreasing risk, increasing speed, and lowering the failure rate for antibody therapeutic development”, said the company.

Read More on PMLiVE